Format

Send to

Choose Destination
Eur J Neurol. 2009 Jan;16(1):21-6. doi: 10.1111/j.1468-1331.2008.02264.x. Epub 2008 Aug 23.

Neutralizing antibodies against interferon β: fluctuation is modest and titre dependent.

Author information

1
Karolinska Institutet, Department of Clinical Neuroscience, Division of Neurology R54, Karolinska University Hospital Huddinge, Stockholm, Sweden.

Abstract

BACKGROUND AND PURPOSE:

Neutralizing antibody (NAb) titres may vary over time and thereby some patients can either lose or regain therapeutic effect of interferon beta (IFNbeta). We assessed NAb titres in a large sample of multiple sclerosis (MS) patients to identify the pattern of fluctuation during 1-3 years.

METHODS:

Data from IFNbeta-treated MS patients who had been tested for NAbs twice (n = 822) were analysed. NAb titres were compared between the first and the second samples across the critical NAb level of 150 TRU/ml, which we have previously reported to correlate with loss of bioactivity.

RESULTS:

Of patients with NAb titres high enough to indicate loss of bioactivity (>150 TRU/ml) in the first analysis 15% showed titres low enough to indicate a regained bioactivity. Conversely, 6% of those without detectable NAbs or NAb titres below the critical level of 150 TRU/ml had shifted to titres above this limit, indicating potential loss of bioactivity. Fluctuation did not differ between IFNbeta preparation used, treatment duration or sampling interval.

CONCLUSION:

A first NAb test is prognostic for the NAb status during the coming 1-3 years. Choice of IFNbeta preparation had no influence on the chance of reverting to lower levels once NAb titres are high.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center